Current Report Filing (8-k)
November 22 2016 - 3:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): November 16, 2016
OPIANT PHARMACEUTICALS, INC.
(
Exact name of registrant as specified
in its charter)
Nevada
|
|
000-55330
|
|
46-4744124
|
(State or
other jurisdiction of incorporation)
|
|
(Commission File Number
|
|
(IRS Employer Identification No.)
|
401 Wilshire Blvd., 12th Floor,
Santa Monica, CA
|
|
90401
|
(Address of Principal Executive Offices)
|
|
(Zip Cope)
|
Registrant’s telephone number, including
area code
(424) 252-4756
|
(Former name or former address if changed since last report,)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
On November 16, 2016, the board of
directors (the “Board”) of Opiant Pharmaceuticals, Inc. (the “Company”) voted to amend and restate the
Company’s Bylaws (the “Amended and Restated Bylaws”) to, effective as of November 16, 2016, (i) reflect the
Company’s current name and (ii) augment Section 3.14 of the Bylaws to allow for e-mail or other electronic transmission
consenting to an action to be taken by a director to be deemed to be a written, signed and dated consent of such director for
the purposes of such Section 3.14.
The foregoing summary of the Amended and
Restated Bylaws is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, which is attached hereto as Exhibit
3.5 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
Description of Exhibit
|
3.5
|
Amended and Restated Bylaws of Opiant Pharmaceuticals, Inc.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Opiant Pharmaceuticals, Inc.
|
|
|
|
Date: November 22, 2016
|
By:
|
/s/
Dr. Roger Crystal
|
|
|
Name: Dr. Roger Crystal
|
|
|
Title: President and Chief Executive Officer
|
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Sep 2023 to Sep 2024